Membrane vesicles in ovarian cancer fluids: A new potential marker

被引:0
|
作者
Ginestra, A
Miceli, D
Dolo, V
Romano, FM
Vittorelli, ML
机构
[1] Dipartimento Biol Cellulare & Sviluppo, I-90128 Palermo, Italy
[2] Osped M Ascoli ARNAS, Div Ginecol Oncol, Palermo, Italy
[3] Ctr Oncobiol Sperimentale, Palermo, Italy
关键词
ovarian cancer; shed vesicles; tumor progression; matrix metalloproteinases;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The rate of membrane vesicle shedding by tumor cells is probably related to their invasive capability. In order to verify whether the vesicle amount could be utilized as a marker of different pathologies, we analyzed biological fluids obtained from 33 patients with gynecological diseases. In fluids of benign serous cysts, vesicle content was extremely low; in cystoadenomas and fibromas generally it was low. On the contrary, large amounts of vesicles were found in malignant tumor fluids. Gelatin zymographies showed the presence of MMP-2 and MMP-9 in all vesicles except in those recovered from fluids of some serous cysts. A positive correlation between tumor malignancy and both vesicle-amount and vesicle-associated MMP-2 activity was noticed. We also analyzed vesicle content in ascitic fluids recovered from two carcinomas at different times during clinical treatment. In both cases, tumor progression, not monitored by Ca 125 levels, was pointed out by an increased amount of vesicles in ascites. These findings suggest that vesicle content in biological fluids could represent a new useful marker of tumor aggressiveness and tumor progression.
引用
收藏
页码:3439 / 3445
页数:7
相关论文
共 50 条
  • [31] Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy
    Zhang, Yingxuan
    Fang, Zheyan
    Li, Ruizhen
    Huang, Xiaotian
    Liu, Qiong
    CANCERS, 2019, 11 (09)
  • [32] MEMBRANE-ASSOCIATED IMMUNOGLOBULINS IN CYST AND ASCITES FLUIDS OF OVARIAN-CANCER PATIENTS
    TAYLOR, DD
    HOMESLEY, HD
    DOELLGAST, GJ
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1983, 3 (01): : 7 - 11
  • [33] Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology
    Mok, SC
    Chao, J
    Skates, S
    Wong, KK
    Yiu, GK
    Muto, MG
    Berkowitz, RS
    Cramer, DW
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (19) : 1458 - 1464
  • [34] PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer
    Chai, Hong-Juan
    Ren, Qing
    Fan, Qin
    Ye, Liu
    Du, Guang-Ye
    Du, Hua-Wen
    Xu, Wei
    Li, Yue
    Zhang, Lan
    Cheng, Zhong-Ping
    ONCOLOGY LETTERS, 2017, 14 (05) : 5871 - 5875
  • [35] Autophagy in clear cell ovarian cancer, a potential marker for hypoxia and poor prognosis?
    Gibson, Spencer B.
    JOURNAL OF PATHOLOGY, 2012, 228 (04): : 434 - 436
  • [36] αvβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer
    Ahmed, N
    Riley, C
    Rice, GE
    Quinn, MA
    Baker, MS
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2002, 50 (10) : 1371 - 1379
  • [37] Valosin containing protein (VCP) is a potential novel serum marker for ovarian cancer
    Nadeau, Marie-Eve
    Lague, Marie-Noelle
    Pouletty, Nicolas
    Boerboom, Derek
    CANCER RESEARCH, 2011, 71
  • [38] Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications
    Kalita-de Croft, Priyakshi
    Sharma, Shayna
    Godbole, Nihar
    Rice, Gregory E.
    Salomon, Carlos
    CELLS, 2021, 10 (09)
  • [39] Overview of CD24 as a new molecular marker in ovarian cancer
    Tarhriz, Vahideh
    Bandehpour, Mojgan
    Dastmalchi, Siavoush
    Ouladsahebmadarek, Elaheh
    Zarredar, Habib
    Eyvazi, Shirin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2134 - 2142
  • [40] A new tumour marker assay for ovarian cancer on the OPUS immunoassay system
    Molz, P
    Teuter, C
    Schelp, C
    Amann, E
    ANTICANCER RESEARCH, 1997, 17 (4B) : 3051 - 3053